Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Innate Pharma    IPH   FR0010331421

INNATE PHARMA

(IPH)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
01/12/2021 01/13/2021 01/14/2021 01/15/2021 01/18/2021 Date
3.89(c) 3.782(c) 3.77(c) 3.834(c) 3.91 Last
246 773 414 358 327 106 390 775 497 874 Volume
+0.41% -2.78% -0.32% +1.70% +1.98% Change
More quotes
Financials
Sales 2020 85,7 M 104 M 104 M
Net income 2020 -30,8 M -37,2 M -37,2 M
Net cash position 2020 152 M 183 M 183 M
P/E ratio 2020 -5,58x
Yield 2020 -
Sales 2021 66,6 M 80,4 M 80,4 M
Net income 2021 -63,8 M -77,0 M -77,0 M
Net cash position 2021 36,1 M 43,6 M 43,6 M
P/E ratio 2021 -3,79x
Yield 2021 -
Capitalization 309 M 373 M 373 M
EV / Sales 2020 1,83x
EV / Sales 2021 4,09x
Nbr of Employees 247
Free-Float 75,3%
More Financials
Company
Innate Pharma specializes in the research and development of immunological-based drugs for cancers and infectious diseases treatment. The drug candidates belong to a new therapeutic class and are monoclonal antibodies targeting mechanisms of regulation of a particular compartment in our immune system: the innate immunity. This approach receives validating partnerships with 2 main players of the biopharmacy:... 
More about the company
Notations Surperformance© of Innate Pharma
Trading Rating : Investor Rating :
More Ratings
All news about INNATE PHARMA
01/05SECTOR UPDATE : Health Care Stocks Mixed Premarket Tuesday
MT
01/05ETF PREVIEW : ETFs, Futures Log Gains Ahead of Georgia Senate Election Runoff Re..
MT
01/05SANOFI : Innate Pharma Shares Rise as Sanofi Selects its Anti-Tumor Drug Candida..
MT
01/05Sanofi Selects Innate's First NK Cell Engager as Anti-Tumor Drug Candidate fo..
MT
01/05Innate's First NK Cell Engager Selected by Sanofi as Drug Candidate for Devel..
GL
01/05INNATE PHARMA : first NK cell engager selected by Sanofi as drug candidate for d..
GL
01/04Innate Pharma to Participate in Upcoming Investor Conferences
GL
01/04INNATE PHARMA : to participate in upcoming investor conferences
GL
2020INNATE PHARMA S A : SVB Leerink Downgrades Innate Pharma to Market Perform From ..
MT
2020INNATE PHARMA S A : HC Wainwright Adjusts Innate Pharma's Price Target to $11.50..
MT
2020INNATE PHARMA : to return US and EU Lumoxiti commercialization rights to AstraZe..
AQ
2020MIDDAY REPORT : Wall Street Weaker Midday On Stimulus Woes
MT
2020SECTOR UPDATE : Health Care Stocks Trade Lower Premarket Friday
MT
2020INNATE PHARMA S A : to Give Up License to AstraZeneca's Leukemia Drug Due to Low..
MT
2020Innate Pharma To Return Immunotoxin's Commercialization Rights In US, EU To A..
MT
More news
News in other languages on INNATE PHARMA
01/05INNATE PHARMA : sa collaboration avec Sanofi progresse, le cours en profite
01/05INNATE PHARMA : plus forte hausse du SRD à la mi-séance du mardi 5 janvier 2021
01/05STOCK MARKET PARIS : Les valeurs à suivre à Paris et en Europe
01/05INNATE PHARMA : La valeur du jour à Paris INNATE PHARMA débute bien l'année
01/05Les valeurs à suivre aujourd'hui à la Bourse de Paris
More news
Analyst Recommendations on INNATE PHARMA
More recommendations
Chart INNATE PHARMA
Duration : Period :
Innate Pharma Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INNATE PHARMA
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 7,23 €
Last Close Price 3,91 €
Spread / Highest target 181%
Spread / Average Target 84,8%
Spread / Lowest Target -23,3%
EPS Revisions
Managers and Directors
NameTitle
Mondher Mahjoubi Chairman-Executive Board & Chief Executive Officer
Hervé Eloi Dominique Brailly Chairman-Supervisory Board
Laure-Hélène Mercier CFO & Member-Executive Board
Eric Vivier Chief Scientific Officer & Senior Vice President
Odile Belzunce Senior VP-Compliance & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
INNATE PHARMA10.75%366
MODERNA, INC.24.10%51 304
LONZA GROUP AG3.27%49 041
CELLTRION, INC.-12.53%40 715
IQVIA HOLDINGS INC.4.81%36 004
SEAGEN INC.6.06%33 601